Lessons learned from the PCSK9 inhibitor trials
Pediatric News ,
LOS ANGELES – Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduce cardiovascular events in chronic and…
恩利西肽获批背后：口服大环肽跨越成药门槛，PCSK9竞争走向分化
sina.com.cn,
看看你关注的PCSK9管线竞争格局究竟如何 系统性地回顾一下赛道内的实力玩家可以发现： 1.注射用抗PCSK9单抗 依洛尤单抗(Amgen) | 阿利西尤单抗(Sanofi/Regeneron) | 托莱西单抗(信达生物) | 瑞卡西单抗(恒瑞医药) 依洛尤…
ODYSSEY Outcomes: Alirocumab cut stroke, PAD, VTE
Pediatric News ,
PHILADELPHIA – Treatment with the PCSK9 inhibitor alirocumab linked with a significant cut in the rates of peripheral artery…
ICYMI: Alirocumab improves cardiovascular outcomes
Pediatric News ,
November 7, 2018|Cardiology Christopher Palmer FROM THE NEW ENGLAND JOURNAL OF MEDICINE Among patients in the ODYSSEY Outcomes…